Therefore, in PG-DLBCL without rituximab, low CD4:CD8 ratio was associated with poor prognosis, while in patients with rituximab maintenance therapy, the CD4:CD8 ratio could not be identified as a prognostic factor. This evidence concerns the gene CD8A and diffuse large B-cell lymphoma.